Publication | Open Access

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

Gastrointestinal OncologyMedicinePharmacologyColorectal CancerPathologyMetastatic Colorectal CancerFirst-line TreatmentPhase Iii StudyCancer TreatmentOncologyRadiation OncologyMolecular Oncology